SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 10,653.85 |
| Enterprise Value ($M) | 11,827.03 |
| Book Value ($M) | 3,240.14 |
| Book Value / Share | 14.25 |
| Price / Book | 3.29 |
| NCAV ($M) | -846.89 |
| NCAV / Share | -3.72 |
| Price / NCAV | -12.58 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.10 |
| Return on Assets (ROA) | 0.09 |
| Return on Equity (ROE) | 0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.85 |
| Current Ratio | 2.19 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2,097.25 |
| Assets | 6,184.28 |
| Liabilities | 2,944.14 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2,251.66 |
| Operating Income | 669.35 |
| Net Income | 512.60 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 639.00 |
| Cash from Investing | -202.43 |
| Cash from Financing | -150.37 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Massachusetts Financial Services Co /ma/ | 9.00 | 73.61 | |
| 13G/A | BlackRock Inc. | 13.50 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 89,451 | 703,474 | 12.72 | |
| 120,539 | 914,074 | 13.19 | |
| 90,188 | 1,015,704 | 8.88 | |
| 69,765 | 634,035 | 11.00 | |
(click for more detail) |
|||
(click for list of largest short owners) |
|||
| Similar Companies | |
|---|---|
| PBH – Prestige Brands Holdings, Inc. | PFE – Pfizer Inc. |
| PRGO – Perrigo Company PLC | RCUS – Arcus Biosciences Inc |
| RDY – Dr. Reddy's Laboratories Ltd. |
Financial data and stock pages provided by
Fintel.io